In previous trials using TIL therapy in patients with metastatic melanoma, a significant correlation was seen between clinical benefit and culture time, percentage of CD8+ and CD8+/CD27+ cells and the absolute number of infused tumor reactive T cells in the in the infusion product [8, 17, 18, 35]. The gene discussed is CD8A; the disease is metastatic melanoma.